See‐Tong Pang
- Bioengineering top 2%
- Analytical Chemistry and Sensors 23
- Cancer Research top 10%
-
- Prostate Cancer Treatment and Research 31
- Renal cell carcinoma treatment 23
- Prostate Cancer Diagnosis and Treatment 17
- Oncology top 10%
- Biomaterials top 10%
-
- Bladder and Urothelial Cancer Treatments 28
- Urinary and Genital Oncology Studies 16
-
- Gas Sensing Nanomaterials and Sensors 18
-
- Renal and related cancers 11
See‐Tong Pang
159 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 130
- Bioengineering 221
- Cancer Research 276
- Pulmonary and Respiratory Medicine 581
- Oncology 440
- Biomaterials 186
Countries citing papers authored by See‐Tong Pang
This map shows the geographic impact of See‐Tong Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by See‐Tong Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites See‐Tong Pang more than expected).
Fields of papers citing papers by See‐Tong Pang
This network shows the impact of papers produced by See‐Tong Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by See‐Tong Pang. The network helps show where See‐Tong Pang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside See‐Tong Pang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 7 | |
| 12 | 2023 | 5 | |
| 13 | 2022 | 10 | |
| 14 | 2022 | 11 | |
| 15 | 2021 | 3 | |
| 16 | Normal lung attenuation distribution and lung volume on computed tomography in a Chinese population | 2019 | 3 |
| 17 | 2018 | 9 | |
| 18 | 2018 | 17 | |
| 19 | 2015 | 2 | |
| 20 | Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. | 2009 | 16 |
About See‐Tong Pang
See‐Tong Pang is a scholar working on Bioengineering, Pulmonary and Respiratory Medicine and Cancer Research, having authored 174 papers that have together received 2.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (31 papers), Bladder and Urothelial Cancer Treatments (28 papers), Renal cell carcinoma treatment (23 papers), Analytical Chemistry and Sensors (23 papers), Gas Sensing Nanomaterials and Sensors (18 papers), Prostate Cancer Diagnosis and Treatment (17 papers), Urinary and Genital Oncology Studies (16 papers) and Renal and related cancers (11 papers). The work is most often cited by research in Bioengineering (221 citations), Cancer Research (276 citations) and Pulmonary and Respiratory Medicine (581 citations). See‐Tong Pang has collaborated with scholars based in Taiwan, United States and Sweden. Frequent co-authors include Cheng‐Keng Chuang, Tung-Ming Pan, Hung‐Wei Yang, Ying‐Hsu Chang, Åke Pousette, Wen‐Hui Weng, Gunnar Norstedt, Amilcar Flores‐Morales, Mu‐Yi Hua and Jim-Long Her. Their work appears in journals such as Nucleic Acids Research, Advanced Materials and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.